|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Amarin Corp. plc, of London, acquired global rights to an oral formulation of apomorphine for the treatment of "off" episodes in patients with advanced Parkinson's disease. The formulation provides absorption of apomorphine directly into the bloodstream after sublingual administration and has completed a proof-of-concept study that demonstrated oral bioavailability in human volunteers. Amarin acquired the rights from Anthony Clarke, Amarin's vice president of clinical development. Amarin is paying a small up-front payment, plus potential success milestones and royalties.
o AMDL Inc., of Tustin, Calif., said its board unanimously approved the stock purchase ...